Oculis Holding AG
OCS
Company Profile
Business description
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Contact
Bahnhofstrasse 20
Zug6300
CHET: +41 417119325
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
49
Stocks News & Analysis
stocks
Are investors too bearish on Australian equities?
A new report suggests the pessimism might be overdone.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,218.80 | 79.60 | -0.86% |
| CAC 40 | 8,219.80 | 3.22 | 0.04% |
| DAX 40 | 24,268.88 | 9.75 | -0.04% |
| Dow JONES (US) | 47,706.37 | 161.78 | 0.34% |
| FTSE 100 | 9,755.00 | 58.26 | 0.60% |
| HKSE | 26,346.14 | 87.56 | -0.33% |
| NASDAQ | 23,827.49 | 190.04 | 0.80% |
| Nikkei 225 | 51,307.65 | 1,088.47 | 2.17% |
| NZX 50 Index | 13,409.21 | 6.55 | 0.05% |
| S&P 500 | 6,890.89 | 15.73 | 0.23% |
| S&P/ASX 200 | 8,926.20 | 85.90 | -0.95% |
| SSE Composite Index | 3,988.22 | 8.72 | -0.22% |